232 related articles for article (PubMed ID: 31702631)
21. Sacral neuromodulation for detrusor hyperactivity with impaired contractility.
Hennessey DB; Hoag N; Gani J
Neurourol Urodyn; 2017 Nov; 36(8):2117-2122. PubMed ID: 28345779
[TBL] [Abstract][Full Text] [Related]
22. [Sacral neuromodulation for refractory overactive bladder].
van Ophoven A
Urologe A; 2018 Nov; 57(11):1375-1388. PubMed ID: 30310935
[TBL] [Abstract][Full Text] [Related]
23. Central inhibition of refractory overactive bladder complaints, results of an inpatient training program.
Meijer EF; Nieuwhof-Leppink AJ; Dekker-Vasse E; de Joode-Smink GC; de Jong TP
J Pediatr Urol; 2015 Feb; 11(1):21.e1-5. PubMed ID: 25205144
[TBL] [Abstract][Full Text] [Related]
24. Sacral neuromodulation system for treating refractory overactive bladder.
Phillips A
Br J Nurs; 2020 Oct; 29(18):S30-S37. PubMed ID: 33035097
[TBL] [Abstract][Full Text] [Related]
25. Affective symptoms and quality of life in patients with voiding or storage dysfunction: Results before and after sacral neuromodulation: A prospective follow-up study.
Jairam R; Drossaerts J; Vrijens D; Leue C; van Kerrebroeck P; van Koeveringe G
Neurourol Urodyn; 2018 Jun; 37(5):1801-1808. PubMed ID: 29504634
[TBL] [Abstract][Full Text] [Related]
26. Overactive Bladder.
White N; Iglesia CB
Obstet Gynecol Clin North Am; 2016 Mar; 43(1):59-68. PubMed ID: 26880508
[TBL] [Abstract][Full Text] [Related]
27. Development of an implant technique and early experience using a novel implantable pulse generator with a quadripolar electrode array at the tibial nerve for refractory overactive bladder.
Sirls LT; Schonhoff A; Waldvogel A; Peters KM
Neurourol Urodyn; 2023 Feb; 42(2):427-435. PubMed ID: 36573835
[TBL] [Abstract][Full Text] [Related]
28. [Sacral neuromodulation in under- and overactive detrusor-quo vadis? : Principles and developments].
Girtner F; Burger M; Mayr R
Urologe A; 2019 Jun; 58(6):634-639. PubMed ID: 31139864
[TBL] [Abstract][Full Text] [Related]
29. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder.
Noblett K; Siegel S; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Berg KC
Neurourol Urodyn; 2016 Feb; 35(2):246-51. PubMed ID: 25546568
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder.
Arlandis S; Castro D; Errando C; Fernández E; Jiménez M; González P; Crespo C; Staeuble F; Rodríguez JM; Brosa M
Value Health; 2011; 14(2):219-28. PubMed ID: 21402292
[TBL] [Abstract][Full Text] [Related]
31. Is sacral neuromodulation effective in patients with Parkinson's disease? A retrospective review.
Martin S; Zillioux J; Goldman HB
Neurourol Urodyn; 2022 Apr; 41(4):955-961. PubMed ID: 35238421
[TBL] [Abstract][Full Text] [Related]
32. Outcomes in a contemporary cohort undergoing sacral neuromodulation using optimized lead placement technique.
Adelstein SA; Lee W; Gioia K; Moskowitz D; Stamnes K; Lucioni A; Kobashi KC; Lee UJ
Neurourol Urodyn; 2019 Aug; 38(6):1595-1601. PubMed ID: 31044466
[TBL] [Abstract][Full Text] [Related]
33. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
[TBL] [Abstract][Full Text] [Related]
34. Sacral neuromodulation in patients with refractory overactive bladder symptoms after failed Botulinum toxin therapy: Results in a large cohort of patients.
Reekmans M; Janssen JMW; Vrijens DMJ; Smits MAC; van Koeveringe GA; Van Kerrebroeck PEVA
Neurourol Urodyn; 2021 Jun; 40(5):1120-1125. PubMed ID: 33829519
[TBL] [Abstract][Full Text] [Related]
35. Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects.
Tilborghs S; De Wachter S
Expert Rev Med Devices; 2022 Feb; 19(2):161-187. PubMed ID: 35061951
[TBL] [Abstract][Full Text] [Related]
36. Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder.
Kantartzis K; Shepherd J
Curr Opin Obstet Gynecol; 2012 Oct; 24(5):331-6. PubMed ID: 22922403
[TBL] [Abstract][Full Text] [Related]
37. Patient preferences for treating refractory overactive bladder in the UK.
Hashim H; Beusterien K; Bridges JF; Amos K; Cardozo L
Int Urol Nephrol; 2015 Oct; 47(10):1619-27. PubMed ID: 26347077
[TBL] [Abstract][Full Text] [Related]
38. Sensing in Sacral Neuromodulation: A Feasibility Study in Subjects With Urinary Incontinence and Retention.
Goudelocke C; Jungbauer Nikolas LM; Bittner KC; Offutt SJ; Miller AE; Slopsema JP
Neuromodulation; 2024 Feb; 27(2):392-398. PubMed ID: 37589643
[TBL] [Abstract][Full Text] [Related]
39. The effect of sacral neuromodulation on pudendal nerve function and female sexual function.
Parnell BA; Howard JF; Geller EJ
Neurourol Urodyn; 2015 Jun; 34(5):456-60. PubMed ID: 24615871
[TBL] [Abstract][Full Text] [Related]
40. Electroacupuncture for post-stroke overactive bladder: a multi-centre pilot randomized controlled trial.
Chen H; Wang C; Zhou M; Yan Chan P; Lo Yam L; Lok Lam W; Leung KP; Li SW; Tsang WY; Fung-Leung Ng B; Tat-Chi Ziea E; Yeung WF; Lao L
Acupunct Med; 2021 Jun; 39(3):175-183. PubMed ID: 32646228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
